Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic attacks; leukopenia; neurotoxicity; peripheral neuropathy; and thrombocytopenia. Some lesser side effects that may not need medical attention include blurred vision, change in taste or metallic taste, cold sores or stomatitis, diarrhea, dizziness, dry mouth, dry skin or itching, flu-like syndrome, increased sweating, leg cramps, loss of appetite, nausea or vomiting, skin rash, unusual tiredness, weight loss, and partial loss of hair.
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-2a. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2a. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2a. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2a. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2a. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2a. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2a. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2a. |
| Adalimumab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Adalimumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Gemtuzumab ozogamicin. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Pegaspargase. |
| Infliximab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Infliximab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Interferon beta-1b. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Interferon alfacon-1. |
| Rituximab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Rituximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Basiliximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Muromonab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Alemtuzumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Alefacept. |
| Efalizumab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Interferon alfa-2b. |
| Daclizumab | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daclizumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Phenylalanine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Flunisolide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bortezomib. |
| Cladribine | Interferon alfa-2a may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carmustine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Amsacrine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fludarabine. |